简体|繁體
NEWS CORNER
Year:
2017
22/05/2017AC Immune and Essex Bio-Technology announce research collaboration for neurodegenerative diseases and neuroinflammation
2016
07/04/2016HUMACYTE,INC.,one of the investments of the group,made research and development progress in Q1 2016
21/03/2016Group turnover and profit recorded growth of 26.2% to HK$654M & 39.4% to HK$104.9 respectively
2015
28/08/2015EssexBio and Tasly to co-develop recombinant protein drugs under Strategic Co-Operation Framework Agreement
18/03/2015Group turnover and profit recorded growth of 49.3% & 37.1% respectively
2014
07/08/2014Growth of 40.1% & 13.8% in turnover and profit respectively
15/05/2014Announcement obtaining of a health food certificate by a wholly-owned subsidiary
28/04/2014Zhuhai Essex Bio-Pharmaceutical Company Limited Bestowed the Award of Outstanding Enterprise of 2013(Guangdong Province)
17/02/2014Announcement import and service agreement with Pfizer international trading (ShangHai) LTD.
2013
31/12/2013Obtaining of a certificate of good manufacturing practices for human drugs by a wholly-owed subsidiary
2011
03/08/2011Group recorded first half growth of 53.6% & 34.4% in turnover and profit respectively
23/06/2011Essex Bio-Technology Limited successfully transferred the listing from the gem board to the main board (stock code on main board: 1061) (stock code on gem: 8151)
12/05/2011Group pharmaceutical business recorded first quarter growth of 74.3% & 44.0% in turnover and profit respectively
28/03/2011Group pharmaceutical business recorded growth of 25.4% & 58.7% in turnover and profit respectively
2010
04/11/2010Group pharmaceutical business recorded growth of 22.4% & 45.1% in turnover and profit respectively
11/08/2010Group pharmaceutical business recorded growth of 22.6% & 38.3% in turnover and profit respectively
25/03/2010Group pharmaceutical business recorded moderate growth of 25.6% in revenue